CoChat
Sign Up
Cited by 61Neuroendocrine Tumor Research AdvancesPituitary Gland Disorders and TreatmentsPolyamine Metabolism and Applications

Chromogranin A as an Alternative to 5-Hydroxyindoleacetic Acid in the Evaluation of Symptoms during Treatment of Patients with Neuroendocrine Tumors

Korse, Catharina M., Bonfrer, Johannes M.G., Aaronson, Neil K., Hart, Augustinus A.M., Taal, Babs G.·2009·Neuroendocrinology
DOI 10.1159/000162876
Open this paper in CoChat — free account

Abstract

Background: Urinary 5-HIAA excretion is a well-known marker in neuroendocrine tumors (NETs), but it has a low sensitivity and the 24-hour collection is inconvenient for patients. Chromogranin A (CgA) is a promising marker, but a thorough evaluation during follow-up is still lacking. Methods: 39 patients with metastatic gastrointestinal NETs were monitored during treatment with the long-acting octreotide SandostatinLAR®. A comparison was made between serum CgA and urinary 5-HIAA in relation to quality of life (HRQL) assessed by the EORTC QLQ-C30 questionnaire, supplemented with questions specific to carcinoid symptoms. Survival analyses were performed to examine the association between the markers and survival time. Results: Correlations were found between CgA and physical functioning (p = 0.01) and quality of life (p = 0.03), while no significant correlations were observed between 5-HIAA levels and any of the self-reported health outcomes. Cox regression showed an association between CgA levels and survival time (p = 0.02), while no significant association was observed between 5-HIAA levels and survival time. Conclusion: Stronger correlations of CgA compared to 5-HIAA with physical functioning and wellbeing, the convenience of measuring in blood, as well as the prognostic value of CgA for survival, makes CgA the recommended marker in the management of patients with metastatic NETs.

Integrity signals

Registry

Crossref · 10.1159/000162876

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Chromogranin A has replaced 24-h urine collection of 5-hydroxyindoleacetic acid and is the most important tumour marker in monitoring neuroendocrine tumours during and after treatment, and is recommended by the European NeuroEndocrine Tumor Society.

    “Chromogranin A (CgA) has replaced the 24-h urine collection of 5-hydroxyindoleacetic acid and has become the most important tumour marker in the monitoring of NET during and after treatment and is recommended by the European NeuroEndocrine Tumor Society (Korse et al, 2009; O'Toole et al, 2009).”

    From Discontinuation of proton pump inhibitors during assessment of chromogranin A levels in patients with neuroendocrine tumours (2011) · cites this paper as Korse et al, 2009

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Korse, C. M., Bonfrer, J. M. G., Aaronson, N. K., Hart, A. A. M., & Taal, B. G.
Affiliations
The Netherlands Cancer Institute (NL)
ORCID
Venue
Neuroendocrinology
Publisher
S. Karger AG
Published
2008-10-07
Volume
89
Issue
3
Pages
296-301
ISSN
  • 0028-3835 (ISSN-L)
  • 1423-0194
DOI
10.1159/000162876
OpenAlex
W2060487268
Cited by
61
References
23
Citations by year
2026: 3 · 2025: 1 · 2024: 1 · 2022: 1 · 2021: 1 · 2020: 2 · 2019: 3 · 2018: 1 · 2017: 5 · 2016: 6 · 2015: 8 · 2014: 4 · 2013: 4 · 2012: 7
FWCI
3.46
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Neuroendocrinology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Epidemiology › Neuroendocrine Tumor Research Advances
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Polyamine Metabolism and Applications
Keywords
chromogranin A, 5-hydroxyindoleacetic acid, neuroendocrine tumors, octreotide, quality of life, physical function, prognostic factors, survival, tumor marker monitoring
MeSH terms
Adult, Aged, Aged, 80 and over, Carcinoid Tumor, Female, Follow-Up Studies, Gastrointestinal Neoplasms, Humans, Hydroxyindoleacetic Acid, Male, Middle Aged, Neoplasm Metastasis, Quality of Life, Biomarkers, Tumor, Octreotide, Survival Analysis, Neuroendocrine Tumors, Chromogranin A

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review